Clinical Trial

Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer

Study acronym: ACTOv
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a proxy measure of total tumour burden and an individual patient's response to the most recent chemotherapy treatment. AT could prolong sensitivity to carboplatin and extend tumour control, while simultaneously reducing chemotherapy dose and drug-induced toxicity. Carboplatin is a low cost and low toxicity drug that has an enduring and central role in ovarian cancer treatment.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-10-12; most recent amendment 2024-04-11.
Status change: Not Yet Recruiting → Recruiting 2023-04-04
Trial Details
NCT Number NCT05080556
Lead Sponsor University College, London
Collaborators: Anticancer Fund, Belgium, JP Moulton Charitable Foundation, Barts & The London NHS Trust
Conditions Ovarian Cancer, Relapsed Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Endometrioid Carcinoma, High Grade Serous Carcinoma, Ovary Cancer
Enrollment 80 participants
Start Date 2023-05-24
Primary Completion 2026-11-01 (estimated)
Study Completion 2027-11-01 (estimated)
Updated on ClinicalTrials.gov 2024-04-12